Market revenue in 2023 | USD 876.9 million |
Market revenue in 2030 | USD 1,141.1 million |
Growth rate | 3.8% (CAGR from 2023 to 2030) |
Largest segment | Anti- inflammatories |
Fastest growing segment | Combination therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 62.18% in 2023. Horizon Databook has segmented the UK asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The asthma therapeutics market in UK is one of the major markets in the region. The high incidence of respiratory diseases in winter significantly increased the disease burden on the National Health Service (NHS); most respiratory admissions are nonelective, and their number doubles during winter.
The annual economic burden of COPD and asthma on the NHS in the UK is evaluated at USD 2.73 billion (£1.9 billion) and USD 4.12 billion (£3 billion) respectively. Furthermore, the rapid commercialization of products and increasing research initiatives, such as product launches, funding, & collaborations, are expected to fuel market growth.
For instance, in August 2023, Teva UK introduced Go Resp Digihaler, empowering eligible adult patients with asthma & COPD to autonomously manage their conditions and share relevant data with healthcare professionals. Furthermore, in November 2020, Enerzair Breezhaler announced the inaugural of triple combination inhaler for asthma to be introduced in the UK.
Horizon Databook provides a detailed overview of country-level data and insights on the UK asthma therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into UK asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account